On binding to ECM molecules, integrins are thought to undergo a conformational change, which allows the intracellular domain of their β-subunit to interact with focal-adhesion proteins ...

These changes highlight the company’s strategic focus on advancing its pipeline of Focal Adhesion Kinase inhibitors, crucial in cancer and fibrosis treatment. Investors may see this as a sign of ...

This move may signal confidence in Amplia’s ongoing development of Focal Adhesion Kinase inhibitors, which are gaining traction in cancer and fibrosis treatment. Investors might view this as a ...